Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice

Abstract Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not recommend nonstatin therapies or treatment to target low-density lipoprotein cholesterol (...

Full description

Saved in:
Bibliographic Details
Published inJournal of the American College of Cardiology Vol. 64; no. 21; pp. 2183 - 2192
Main Authors Maddox, Thomas M., MD, MSc, Borden, William B., MD, Tang, Fengming, MS, Virani, Salim S., MD, PhD, Oetgen, William J., MD, MBA, Mullen, J. Brendan, BSFS, Chan, Paul S., MD, MSc, Casale, Paul N., MD, Douglas, Pamela S., MD, Masoudi, Fredrick A., MD, MSPH, Farmer, Steven A., MD, PhD, Rumsfeld, John S., MD, PhD
Format Journal Article
LanguageEnglish
Published New York Elsevier Inc 02.12.2014
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Abstract Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not recommend nonstatin therapies or treatment to target low-density lipoprotein cholesterol (LDL-C) levels, limiting the need for repeated LDL-C testing. Objectives The goal of this study was to examine the impact of the 2013 ACC/AHA cholesterol guidelines on current U.S. cardiovascular practice. Methods Using the NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excellence) registry data from 2008 to 2012, we assessed current practice patterns as a function of the 2013 cholesterol guidelines. Lipid-lowering therapies and LDL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease [ASCVD], diabetes, LDL-C ≥190 mg/dl, or an estimated 10-year ASCVD risk ≥7.5%) were described. Results Among a cohort of 1,174,545 patients, 1,129,205 (96.1%) were statin-eligible (91.2% ASCVD, 6.6% diabetes, 0.3% off-treatment LDL-C ≥190 mg/dl, 1.9% estimated 10-year ASCVD risk ≥7.5%). There were 377,311 patients (32.4%) not receiving statin therapy and 259,143 (22.6%) receiving nonstatin therapies. During the study period, 20.8% of patients had 2 or more LDL-C assessments, and 7.0% had more than 4. Conclusions In U.S. cardiovascular practices, 32.4% of statin-eligible patients, as defined by the 2013 ACC/AHA cholesterol guidelines, were not currently receiving statins. In addition, 22.6% were receiving nonstatin lipid-lowering therapies and 20.8% had repeated LDL-C testing. Achieving concordance with the new cholesterol guidelines in patients treated in U.S. cardiovascular practices would result in significant increases in statin use, as well as significant reductions in nonstatin therapies and laboratory testing.
AbstractList In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not recommend nonstatin therapies or treatment to target low-density lipoprotein cholesterol (LDL-C) levels, limiting the need for repeated LDL-C testing. The goal of this study was to examine the impact of the 2013 ACC/AHA cholesterol guidelines on current U.S. cardiovascular practice. Using the NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excellence) registry data from 2008 to 2012, we assessed current practice patterns as a function of the 2013 cholesterol guidelines. Lipid-lowering therapies and LDL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease [ASCVD], diabetes, LDL-C ≥190 mg/dl, or an estimated 10-year ASCVD risk ≥7.5%) were described. Among a cohort of 1,174,545 patients, 1,129,205 (96.1%) were statin-eligible (91.2% ASCVD, 6.6% diabetes, 0.3% off-treatment LDL-C ≥190 mg/dl, 1.9% estimated 10-year ASCVD risk ≥7.5%). There were 377,311 patients (32.4%) not receiving statin therapy and 259,143 (22.6%) receiving nonstatin therapies. During the study period, 20.8% of patients had 2 or more LDL-C assessments, and 7.0% had more than 4. In U.S. cardiovascular practices, 32.4% of statin-eligible patients, as defined by the 2013 ACC/AHA cholesterol guidelines, were not currently receiving statins. In addition, 22.6% were receiving nonstatin lipid-lowering therapies and 20.8% had repeated LDL-C testing. Achieving concordance with the new cholesterol guidelines in patients treated in U.S. cardiovascular practices would result in significant increases in statin use, as well as significant reductions in nonstatin therapies and laboratory testing.
Abstract Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not recommend nonstatin therapies or treatment to target low-density lipoprotein cholesterol (LDL-C) levels, limiting the need for repeated LDL-C testing. Objectives The goal of this study was to examine the impact of the 2013 ACC/AHA cholesterol guidelines on current U.S. cardiovascular practice. Methods Using the NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excellence) registry data from 2008 to 2012, we assessed current practice patterns as a function of the 2013 cholesterol guidelines. Lipid-lowering therapies and LDL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease [ASCVD], diabetes, LDL-C ≥190 mg/dl, or an estimated 10-year ASCVD risk ≥7.5%) were described. Results Among a cohort of 1,174,545 patients, 1,129,205 (96.1%) were statin-eligible (91.2% ASCVD, 6.6% diabetes, 0.3% off-treatment LDL-C ≥190 mg/dl, 1.9% estimated 10-year ASCVD risk ≥7.5%). There were 377,311 patients (32.4%) not receiving statin therapy and 259,143 (22.6%) receiving nonstatin therapies. During the study period, 20.8% of patients had 2 or more LDL-C assessments, and 7.0% had more than 4. Conclusions In U.S. cardiovascular practices, 32.4% of statin-eligible patients, as defined by the 2013 ACC/AHA cholesterol guidelines, were not currently receiving statins. In addition, 22.6% were receiving nonstatin lipid-lowering therapies and 20.8% had repeated LDL-C testing. Achieving concordance with the new cholesterol guidelines in patients treated in U.S. cardiovascular practices would result in significant increases in statin use, as well as significant reductions in nonstatin therapies and laboratory testing.
Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin therapy for those at risk and do not recommend nonstatin therapies or treatment to target low-density lipoprotein cholesterol (LDL-C) levels, limiting the need for repeated LDL-C testing. Objectives The goal of this study was to examine the impact of the 2013 ACC/AHA cholesterol guidelines on current U.S. cardiovascular practice. Methods Using the NCDR PINNACLE (National Cardiovascular Data Registry Practice Innovation and Clinical Excellence) registry data from 2008 to 2012, we assessed current practice patterns as a function of the 2013 cholesterol guidelines. Lipid-lowering therapies and LDL-C testing patterns by patient risk group (atherosclerotic cardiovascular disease , diabetes, LDL-C >=190 mg/dl, or an estimated 10-year ASCVD risk >=7.5%) were described. Results Among a cohort of 1,174,545 patients, 1,129,205 (96.1%) were statin-eligible (91.2% ASCVD, 6.6% diabetes, 0.3% off-treatment LDL-C >=190 mg/dl, 1.9% estimated 10-year ASCVD risk >=7.5%). There were 377,311 patients (32.4%) not receiving statin therapy and 259,143 (22.6%) receiving nonstatin therapies. During the study period, 20.8% of patients had 2 or more LDL-C assessments, and 7.0% had more than 4. Conclusions In U.S. cardiovascular practices, 32.4% of statin-eligible patients, as defined by the 2013 ACC/AHA cholesterol guidelines, were not currently receiving statins. In addition, 22.6% were receiving nonstatin lipid-lowering therapies and 20.8% had repeated LDL-C testing. Achieving concordance with the new cholesterol guidelines in patients treated in U.S. cardiovascular practices would result in significant increases in statin use, as well as significant reductions in nonstatin therapies and laboratory testing.
Author Maddox, Thomas M., MD, MSc
Chan, Paul S., MD, MSc
Mullen, J. Brendan, BSFS
Masoudi, Fredrick A., MD, MSPH
Oetgen, William J., MD, MBA
Borden, William B., MD
Rumsfeld, John S., MD, PhD
Casale, Paul N., MD
Virani, Salim S., MD, PhD
Tang, Fengming, MS
Farmer, Steven A., MD, PhD
Douglas, Pamela S., MD
Author_xml – sequence: 1
  fullname: Maddox, Thomas M., MD, MSc
– sequence: 2
  fullname: Borden, William B., MD
– sequence: 3
  fullname: Tang, Fengming, MS
– sequence: 4
  fullname: Virani, Salim S., MD, PhD
– sequence: 5
  fullname: Oetgen, William J., MD, MBA
– sequence: 6
  fullname: Mullen, J. Brendan, BSFS
– sequence: 7
  fullname: Chan, Paul S., MD, MSc
– sequence: 8
  fullname: Casale, Paul N., MD
– sequence: 9
  fullname: Douglas, Pamela S., MD
– sequence: 10
  fullname: Masoudi, Fredrick A., MD, MSPH
– sequence: 11
  fullname: Farmer, Steven A., MD, PhD
– sequence: 12
  fullname: Rumsfeld, John S., MD, PhD
BookMark eNp9kcFq3TAQRUVJoS9pf6ArQdd2RrZs2VAKxrRJIJBC27WQR2Mi1896lexA_j4yr1DoIitt7p05OnPJLha_EGMfBeQCRH095ZNBzAsQMocmBynesIOoqiYrq1ZdsAOossoEtOodu4xxAoC6Ee2BTXfH0-zQrM4vkfuRr4_E05iSd31_3d12vH_0M8WVgp_5zeYszW6hyEcfeGe3eY3cLbz3y0rHkw8mPPPeBOv8k4m4zSbw78Hg6pDes7ejmSN9-PtesV_fvv7sb7P7h5u7vrvPsFCFyOwglbAwwGjHYqgLg-kHqh5t1RYSrJVoJRnZ2BJNXReKCHFEFKpth7ExQ3nFPp3nnoL_syV0PfktLGmlFimvZA0lpFRxTmHwMQYa9Sm4Y8LXAvTuVE96d6p3pxoanZym0udziRL_k6OgIzpakKwLhKu23r1e__JfHZPMZH_-Tc8U_2HqWGjQP_aj7TcTEnbwtnwB022Wtw
CitedBy_id crossref_primary_10_1002_clc_22628
crossref_primary_10_1097_RLU_0000000000001884
crossref_primary_10_1016_j_jacc_2014_12_072
crossref_primary_10_1007_s11739_017_1694_9
crossref_primary_10_1016_j_jacl_2021_01_006
crossref_primary_10_1016_j_ijcard_2020_12_064
crossref_primary_10_1016_j_jcct_2015_09_003
crossref_primary_10_1161_CIRCOUTCOMES_121_007908
crossref_primary_10_1136_heartasia_2019_011200
crossref_primary_10_1007_s11886_022_01767_5
crossref_primary_10_1016_j_dsx_2023_102784
crossref_primary_10_1016_j_eurger_2015_05_006
crossref_primary_10_2146_ajhp160050
crossref_primary_10_1007_s00392_016_0991_z
crossref_primary_10_1016_j_ahj_2019_06_005
crossref_primary_10_1016_j_jacc_2022_08_754
crossref_primary_10_1097_JCN_0000000000000443
crossref_primary_10_1016_j_jacc_2015_05_030
crossref_primary_10_1002_clc_22423
crossref_primary_10_1002_clc_23115
crossref_primary_10_1016_j_amjcard_2022_11_039
crossref_primary_10_1016_j_jacc_2014_08_040
crossref_primary_10_1161_JAHA_116_005333
crossref_primary_10_1007_s11764_020_00865_z
crossref_primary_10_1016_j_jdiacomp_2022_108309
crossref_primary_10_1002_clc_22503
crossref_primary_10_1016_j_ihj_2015_05_020
crossref_primary_10_1016_j_jacc_2014_12_022
crossref_primary_10_1016_j_mayocp_2021_02_032
crossref_primary_10_1016_j_tcm_2019_07_002
crossref_primary_10_1016_j_jacl_2015_11_002
crossref_primary_10_1016_j_amjcard_2019_04_017
crossref_primary_10_1016_j_hrtlng_2017_03_005
crossref_primary_10_5694_mja18_00104
crossref_primary_10_2147_CLEP_S259757
crossref_primary_10_5144_0256_4947_2017_276
crossref_primary_10_1016_j_jacl_2019_08_002
crossref_primary_10_1097_HCR_0000000000000779
crossref_primary_10_4158_EP171866_GL
crossref_primary_10_1016_j_ypmed_2019_02_003
crossref_primary_10_3390_jpm12071180
crossref_primary_10_1097_HCR_0000000000000332
crossref_primary_10_1371_journal_pmed_1002007
crossref_primary_10_1161_JAHA_117_005801
crossref_primary_10_1016_j_amjcard_2019_09_033
crossref_primary_10_1038_s43856_022_00157_w
crossref_primary_10_1001_jamacardio_2018_4936
crossref_primary_10_1016_j_amjcard_2015_05_011
crossref_primary_10_1097_RLU_0000000000001900
crossref_primary_10_1016_j_amjcard_2018_10_034
crossref_primary_10_1016_j_ijchy_2020_100075
crossref_primary_10_15212_CVIA_2016_0035
crossref_primary_10_1016_j_jacc_2019_11_011
crossref_primary_10_1161_JAHA_118_011765
crossref_primary_10_1016_j_amjcard_2022_10_013
crossref_primary_10_1097_HCR_0000000000000209
crossref_primary_10_1002_clc_22641
crossref_primary_10_1161_JAHA_117_007132
crossref_primary_10_1161_JAHA_119_015807
crossref_primary_10_1016_j_jacc_2014_12_005
crossref_primary_10_1016_j_pcad_2016_07_010
crossref_primary_10_1002_clc_22963
crossref_primary_10_1007_s12325_020_01285_2
crossref_primary_10_1016_j_jacl_2016_09_002
crossref_primary_10_1016_j_jacadv_2023_100753
crossref_primary_10_1080_03009742_2019_1672782
crossref_primary_10_1161_CIRCOUTCOMES_122_009787
crossref_primary_10_1007_s11739_017_1749_y
crossref_primary_10_1002_jac5_1222
crossref_primary_10_1016_j_ijcard_2024_131933
crossref_primary_10_1016_j_atherosclerosis_2015_12_044
crossref_primary_10_1161_JAHA_117_005627
crossref_primary_10_1016_j_amjcard_2018_12_031
crossref_primary_10_1177_0897190018824820
crossref_primary_10_1016_j_jacc_2015_02_057
crossref_primary_10_1161_JAHA_118_009251
crossref_primary_10_1161_JAHA_117_007370
crossref_primary_10_4103_jfmpc_jfmpc_2125_22
crossref_primary_10_1111_jcpt_12837
crossref_primary_10_1016_j_ahj_2016_09_007
crossref_primary_10_1016_j_jacl_2016_06_011
crossref_primary_10_1161_JAHA_117_007762
crossref_primary_10_1177_1074248420947633
crossref_primary_10_1016_j_ajpc_2022_100336
crossref_primary_10_1210_clinem_dgae116
crossref_primary_10_1016_j_ihj_2017_05_016
crossref_primary_10_1161_JAHA_122_028120
crossref_primary_10_1002_clc_23448
crossref_primary_10_1161_JAHA_116_005205
crossref_primary_10_1016_j_amjcard_2019_07_022
crossref_primary_10_1016_j_ijcard_2016_06_113
Cites_doi 10.1001/jama.2013.281348
10.1016/j.jacc.2013.11.002
10.17226/13059
10.1001/jama.285.19.2486
10.1016/j.jacc.2013.05.099
10.1016/S0140-6736(13)62388-0
10.1016/j.jacc.2013.08.003
10.1016/j.jacc.2013.08.004
10.1056/NEJMoa1315665
10.17226/13058
10.1016/S0140-6736(13)62348-X
10.1016/j.amjmed.2009.09.019
10.1016/j.jacc.2012.07.020
ContentType Journal Article
Copyright American College of Cardiology Foundation
2014 American College of Cardiology Foundation
Copyright Elsevier Limited Dec 2, 2014
Copyright_xml – notice: American College of Cardiology Foundation
– notice: 2014 American College of Cardiology Foundation
– notice: Copyright Elsevier Limited Dec 2, 2014
DBID 6I.
AAFTH
AAYXX
CITATION
7T5
7TK
H94
K9.
NAPCQ
DOI 10.1016/j.jacc.2014.08.041
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
CrossRef
Immunology Abstracts
Neurosciences Abstracts
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitle CrossRef
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
Immunology Abstracts
Neurosciences Abstracts
DatabaseTitleList

AIDS and Cancer Research Abstracts
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1558-3597
EndPage 2192
ExternalDocumentID 3506744931
10_1016_j_jacc_2014_08_041
S0735109714062779
1_s2_0_S0735109714062779
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GroupedDBID ---
--K
--M
.1-
.55
.FO
.GJ
.~1
0R~
0SF
18M
1B1
1CY
1P~
1~.
1~5
29L
2WC
3O-
3V.
4.4
457
4G.
53G
5GY
5RE
5VS
6I.
6PF
7-5
71M
7RV
8P~
AABNK
AABVL
AACTN
AAEDT
AAEDW
AAFTH
AAIKJ
AAKUH
AALRI
AAOAW
AAQFI
AAQQT
AAQXK
AAXUO
AAYOK
ABBQC
ABFNM
ABFRF
ABJNI
ABLJU
ABMAC
ABMZM
ABOCM
ABVKL
ABXDB
ACGFO
ACGFS
ACIUM
ACJTP
ACPRK
ADBBV
ADEZE
ADMUD
ADVLN
AEFWE
AEKER
AENEX
AEVXI
AEXQZ
AFCTW
AFETI
AFFNX
AFRAH
AFRHN
AFTJW
AGHFR
AGYEJ
AHMBA
AITUG
AJOXV
AJRQY
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ASPBG
AVWKF
AZFZN
BAWUL
BENPR
BLXMC
BPHCQ
CS3
DIK
DU5
E3Z
EBS
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FNPLU
G-Q
GBLVA
GX1
H13
HVGLF
HX~
HZ~
IHE
IXB
J1W
J5H
K-O
KQ8
L7B
MO0
N4W
N9A
NCXOZ
O-L
O9-
OA.
OAUVE
OK1
OL~
OZT
P-8
P-9
P2P
PC.
PQQKQ
PROAC
Q38
QTD
R2-
RIG
ROL
RPZ
SCC
SDF
SDG
SDP
SES
SEW
SSZ
T5K
TR2
UNMZH
UV1
W8F
WH7
WOQ
WOW
X7M
XPP
YYM
YYP
YZZ
Z5R
ZGI
ZXP
AAIAV
EFLBG
LCYCR
NAHTW
ZA5
AAYXX
CITATION
7T5
7TK
H94
K9.
NAPCQ
ID FETCH-LOGICAL-c2721-db471d0b0fdf2b62ac59776fd59240dd4cd4ea48d3ca6627eeccfcc1799bf8ab3
IEDL.DBID .~1
ISSN 0735-1097
IngestDate Thu Oct 10 22:51:20 EDT 2024
Thu Sep 12 19:57:12 EDT 2024
Fri Feb 23 02:32:17 EST 2024
Tue Oct 15 22:52:43 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Keywords ACC
secondary prevention
ASCVD
LDL-C
low-density lipoprotein cholesterol
cardiovascular diseases
atherosclerotic cardiovascular disease
Adult Treatment Panel
hydroxymethylglutaryl-coA reductase inhibitors
American College of Cardiology
American Heart Association
cohort studies
primary prevention
cholesterol
AHA
ATP
Language English
License http://www.elsevier.com/open-access/userlicense/1.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2721-db471d0b0fdf2b62ac59776fd59240dd4cd4ea48d3ca6627eeccfcc1799bf8ab3
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0735109714062779
PQID 1627746030
PQPubID 2031078
PageCount 10
ParticipantIDs proquest_journals_1627746030
crossref_primary_10_1016_j_jacc_2014_08_041
elsevier_sciencedirect_doi_10_1016_j_jacc_2014_08_041
elsevier_clinicalkeyesjournals_1_s2_0_S0735109714062779
PublicationCentury 2000
PublicationDate 20141202
PublicationDateYYYYMMDD 2014-12-02
PublicationDate_xml – month: 12
  year: 2014
  text: 20141202
  day: 02
PublicationDecade 2010
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Journal of the American College of Cardiology
PublicationYear 2014
Publisher Elsevier Inc
Elsevier Limited
Publisher_xml – name: Elsevier Inc
– name: Elsevier Limited
References Stone, Robinson, Lichtenstein (bib1) 2014; 63
Chan, Oetgen, Spertus (bib8) 2010; 123
(bib4) 2001; 285
Messenger, Ho, Young (bib9) 2012; 60
Ridker, Cook (bib11) 2013; 382
Pencina, Navar-Boggan, D’Agostino (bib7) 2014; 370
Gibbons, Harold, Jessup, Robertson, Oetgen (bib3) 2013; 62
Gibbons, Shurin, Mensah, Lauer (bib2) 2013; 62
Taylor, Huffman, Ebrahim (bib13) 2013; 310
Eden J, Levit L, Berg A, et al., for the Institute of Medicine, editors. Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press, 2011.
Graham R, Wolman DM, Greenfield S, et al., for the Institute of Medicine, editors. Clinical Practice Guidelines We Can Trust. Washington, DC: National Academies Press, 2011.
Lloyd-Jones, Goff, Stone (bib12) 2014; 383
Masoudi, Ponirakis, Yeh (bib10) 2013; 62
10.1016/j.jacc.2014.08.041_bib6
Lloyd-Jones (10.1016/j.jacc.2014.08.041_bib12) 2014; 383
10.1016/j.jacc.2014.08.041_bib5
Taylor (10.1016/j.jacc.2014.08.041_bib13) 2013; 310
Pencina (10.1016/j.jacc.2014.08.041_bib7) 2014; 370
Messenger (10.1016/j.jacc.2014.08.041_bib9) 2012; 60
Gibbons (10.1016/j.jacc.2014.08.041_bib2) 2013; 62
Chan (10.1016/j.jacc.2014.08.041_bib8) 2010; 123
Gibbons (10.1016/j.jacc.2014.08.041_bib3) 2013; 62
Masoudi (10.1016/j.jacc.2014.08.041_bib10) 2013; 62
Ridker (10.1016/j.jacc.2014.08.041_bib11) 2013; 382
Stone (10.1016/j.jacc.2014.08.041_bib1) 2014; 63
(10.1016/j.jacc.2014.08.041_bib4) 2001; 285
References_xml – volume: 62
  start-page: 1399
  year: 2013
  end-page: 1400
  ident: bib3
  article-title: The next steps in developing clinical practice guidelines for prevention
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Oetgen
– volume: 63
  start-page: 2889
  year: 2014
  end-page: 2934
  ident: bib1
  article-title: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Lichtenstein
– volume: 62
  start-page: 1396
  year: 2013
  end-page: 1398
  ident: bib2
  article-title: Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Lauer
– volume: 60
  start-page: 1484
  year: 2012
  end-page: 1488
  ident: bib9
  article-title: The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The NCDR Data Quality Program in 2012
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Young
– volume: 383
  start-page: 600
  year: 2014
  end-page: 602
  ident: bib12
  article-title: Statins, risk assessment, and the new American prevention guidelines
  publication-title: Lancet
  contributor:
    fullname: Stone
– volume: 62
  start-page: 1931
  year: 2013
  end-page: 1947
  ident: bib10
  article-title: Cardiovascular care facts: a report from the National Cardiovascular Data Registry: 2011
  publication-title: J Am Coll Cardiol
  contributor:
    fullname: Yeh
– volume: 370
  start-page: 1422
  year: 2014
  end-page: 1431
  ident: bib7
  article-title: Application of new cholesterol guidelines to a population-based sample
  publication-title: N Engl J Med
  contributor:
    fullname: D’Agostino
– volume: 285
  start-page: 2486
  year: 2001
  end-page: 2497
  ident: bib4
  article-title: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  publication-title: JAMA
– volume: 123
  start-page: 217
  year: 2010
  end-page: 219
  ident: bib8
  article-title: The Improving Continuous Cardiac Care (IC(3)) program and outpatient quality improvement
  publication-title: Am J Med
  contributor:
    fullname: Spertus
– volume: 382
  start-page: 1762
  year: 2013
  end-page: 1765
  ident: bib11
  article-title: Statins: new American guidelines for prevention of cardiovascular disease
  publication-title: Lancet
  contributor:
    fullname: Cook
– volume: 310
  start-page: 2451
  year: 2013
  end-page: 2452
  ident: bib13
  article-title: Statin therapy for primary prevention of cardiovascular disease
  publication-title: JAMA
  contributor:
    fullname: Ebrahim
– volume: 310
  start-page: 2451
  year: 2013
  ident: 10.1016/j.jacc.2014.08.041_bib13
  article-title: Statin therapy for primary prevention of cardiovascular disease
  publication-title: JAMA
  doi: 10.1001/jama.2013.281348
  contributor:
    fullname: Taylor
– volume: 63
  start-page: 2889
  year: 2014
  ident: 10.1016/j.jacc.2014.08.041_bib1
  article-title: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.11.002
  contributor:
    fullname: Stone
– ident: 10.1016/j.jacc.2014.08.041_bib5
  doi: 10.17226/13059
– volume: 285
  start-page: 2486
  year: 2001
  ident: 10.1016/j.jacc.2014.08.041_bib4
  article-title: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
  publication-title: JAMA
  doi: 10.1001/jama.285.19.2486
– volume: 62
  start-page: 1931
  year: 2013
  ident: 10.1016/j.jacc.2014.08.041_bib10
  article-title: Cardiovascular care facts: a report from the National Cardiovascular Data Registry: 2011
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.05.099
  contributor:
    fullname: Masoudi
– volume: 382
  start-page: 1762
  year: 2013
  ident: 10.1016/j.jacc.2014.08.041_bib11
  article-title: Statins: new American guidelines for prevention of cardiovascular disease
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62388-0
  contributor:
    fullname: Ridker
– volume: 62
  start-page: 1396
  year: 2013
  ident: 10.1016/j.jacc.2014.08.041_bib2
  article-title: Refocusing the agenda on cardiovascular guidelines: an announcement from the National Heart, Lung, and Blood Institute
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.08.003
  contributor:
    fullname: Gibbons
– volume: 62
  start-page: 1399
  year: 2013
  ident: 10.1016/j.jacc.2014.08.041_bib3
  article-title: The next steps in developing clinical practice guidelines for prevention
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2013.08.004
  contributor:
    fullname: Gibbons
– volume: 370
  start-page: 1422
  year: 2014
  ident: 10.1016/j.jacc.2014.08.041_bib7
  article-title: Application of new cholesterol guidelines to a population-based sample
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1315665
  contributor:
    fullname: Pencina
– ident: 10.1016/j.jacc.2014.08.041_bib6
  doi: 10.17226/13058
– volume: 383
  start-page: 600
  year: 2014
  ident: 10.1016/j.jacc.2014.08.041_bib12
  article-title: Statins, risk assessment, and the new American prevention guidelines
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62348-X
  contributor:
    fullname: Lloyd-Jones
– volume: 123
  start-page: 217
  year: 2010
  ident: 10.1016/j.jacc.2014.08.041_bib8
  article-title: The Improving Continuous Cardiac Care (IC(3)) program and outpatient quality improvement
  publication-title: Am J Med
  doi: 10.1016/j.amjmed.2009.09.019
  contributor:
    fullname: Chan
– volume: 60
  start-page: 1484
  year: 2012
  ident: 10.1016/j.jacc.2014.08.041_bib9
  article-title: The National Cardiovascular Data Registry (NCDR) Data Quality Brief: The NCDR Data Quality Program in 2012
  publication-title: J Am Coll Cardiol
  doi: 10.1016/j.jacc.2012.07.020
  contributor:
    fullname: Messenger
SSID ssj0006819
Score 2.1829836
Snippet Abstract Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend...
In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose statin...
Background In a significant update, the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol guidelines recommend fixed-dose...
SourceID proquest
crossref
elsevier
SourceType Aggregation Database
Publisher
StartPage 2183
SubjectTerms Cardiology
Cardiovascular
Cardiovascular disease
cardiovascular diseases
Cholesterol
Classification
cohort studies
Diabetes
Heart attacks
Heart failure
hydroxymethylglutaryl-coA reductase inhibitors
Hypertension
Internal Medicine
Lipids
Medical records
Older people
primary prevention
secondary prevention
Title Implications of the 2013 ACC/AHA Cholesterol Guidelines for Adults in Contemporary Cardiovascular Practice
URI https://www.clinicalkey.es/playcontent/1-s2.0-S0735109714062779
https://dx.doi.org/10.1016/j.jacc.2014.08.041
https://www.proquest.com/docview/1627746030
Volume 64
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8NAEF5KBfEiPrFayx68SWwemzQ5psHa-kLQSm9L9hFokbTY9upvdybZ2FbRg8eEzW6YmZ2ZZb_5hpCLTPrSU662BGw1i6WRY0GWkFpMSuYL3QGtF2iLx6A_ZLcjf1QjSVULg7BK4_tLn154a_OmbaTZno3H7WcwTh_vT-GIELidDhbxMQhGYNNXHyuYRxAWzT1wsIWjTeFMifGapBJpDB1W0Hgy57fg9M1NF7Gnt0d2TdJI4_K_9klN5wdk-8Fcix-SyWANF06nGYWsjsKCHo2TpB33Y5pgG1zkRJi-0ZslUlsh3J1CxkpjZOCY03FO15mqaLIBVKVPpprqiAx71y9J3zJNFCzpwunOUgLCj7KFnanMFYGbSmScCzLlw8nLVopJxXTKQuXJFMngNeg0kxKJ4kQWpsI7JvV8musTQkMtM-VgzaWMIM-zRSRsCcepKLS1B9JrkMtKenxWcmXwCkQ24ShrjrLm2PcSR3cqAfOqChT8lp6bTTTnDp-73OY_FN0g_teXG7bCIQz8uWKz0iNfLYJTsgB83ek_pz0jO_hUYFzcJqkv3pf6HDKVhWgVptgiW3H39e4engaj7ic2befB
link.rule.ids 315,786,790,3525,4521,27600,27955,27956,45618,45696,45907
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT8JAEN4gJurF-Iwo6h68mUof29Iem0YEBWIiJNw23UcTiClE4Opvd6ZsFTR68Npud5uZ3Xlkv_mGkJtM-tJTrrYEHDWLpZFjQZSQWkxK5gvdBK0XaIt-0B6yx5E_qpCkrIVBWKWx_SubXlhr86RhpNmYjceNF9icPt6fQooQuM1mtEW2MRpAXNfd-xfOIwiL7h442sLhpnJmBfKapBJ5DB1W8Hgy5zfv9M1OF86ndUD2TdRI49WPHZKKzo_ITs_cix-TSWcNGE6nGYWwjsKCHo2TpBG3Y5pgH1wkRZi-0oclclsh3p1CyEpjpOCY03FO16mqaLKBVKXPppzqhAxb94OkbZkuCpZ0Ib2zlAD_o2xhZypzReCmEinngkz5kHrZSjGpmE5ZqDyZIhu8BqVmUiJTnMjCVHinpJpPc31GaKhlphwsupQRBHq2iIQtIZ-KQlt7IL0auS2lx2crsgxeosgmHGXNUdYcG1_i6GYpYF6WgYLh0nNziubc4XOX2_yHpmvE__xyY7Nw8AN_rlgv9ci_FsEpWQDG7vyf016T3fag1-XdTv_pguzhmwLw4tZJdfG21JcQtizEVbEtPwA_d-hR
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Implications+of+the+2013+ACC%2FAHA+Cholesterol+Guidelines+for+Adults+in+Contemporary+Cardiovascular+Practice&rft.jtitle=Journal+of+the+American+College+of+Cardiology&rft.au=Maddox%2C+Thomas+M.%2C+MD%2C+MSc&rft.au=Borden%2C+William+B.%2C+MD&rft.au=Tang%2C+Fengming%2C+MS&rft.au=Virani%2C+Salim+S.%2C+MD%2C+PhD&rft.date=2014-12-02&rft.issn=0735-1097&rft.volume=64&rft.issue=21&rft.spage=2183&rft.epage=2192&rft_id=info:doi/10.1016%2Fj.jacc.2014.08.041&rft.externalDBID=ECK1-s2.0-S0735109714062779&rft.externalDocID=1_s2_0_S0735109714062779
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F07351097%2FS0735109714X00227%2Fcov150h.gif